TNFSF10 and glioblastoma: On the other hand, CRISPR/Cas9 mediated silencing of DR5 suppressed bortezomib-mediated re-sensitization of glioblastoma cell lines to TRAIL-induced apoptosis, representing its significant role in determining cell response to TRAIL (40).